Trials
1 active
4 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The target dose of stiripentol will be 50 mg/kg/day with a maximum dose of 3,000 mg/day. Patients allocated to the Stiripentol group will receive this treatment during the first 6 months, and in continuation up to 12 months.”In the company’s words, NCT06465472 on ClinicalTrials.gov
- Tested for
- Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
- Main trialPhase 3
- “Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3.”In the company’s words, NCT06465472 on ClinicalTrials.gov
- Other names
- Diacomit capsule · Diacomit oral suspension
Other drugs for Primary Hyperoxaluria Type 1
Coming up1
- Aug 2030Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT06465472
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2030 | Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 | |
| Phase 4Completed | 13 Jun 2024 | Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies | |
| Phase 2Completed | 18 Dec 2020 | Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria | |
| Phase 1Completed | 27 Aug 2025 | Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026